No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
First Wave of European Biosimilar Aflibercept Launches Commences, with Sandoz’s Afqlir® on the UK Market
On 24 November 2025, Sandoz announced the UK launch of Afqlir®, biosimilar to Regeneron/Bayer’s Eylea® (aflibercept), with launches in major European markets such as Germany and France to follow, and additional European rollouts to occur in 2026.